Showing 1 to 1 of 1 results
zeit.de
🌐 75% Global Worthiness
EU Approves First Alzheimer's Disease Treatment Targeting Disease Processes
The European Commission approved Lecanemab, a new Alzheimer's treatment targeting disease processes, for use in the EU; although effective in slowing progression in early stages for a small subset of patients, it is not a cure and its long-term effects remain uncertain.
EU Approves First Alzheimer's Disease Treatment Targeting Disease Processes
The European Commission approved Lecanemab, a new Alzheimer's treatment targeting disease processes, for use in the EU; although effective in slowing progression in early stages for a small subset of patients, it is not a cure and its long-term effects remain uncertain.
Progress
44% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results